Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy

Clinical Cardiology

Volumn 33, Issue 7, 2010, Pages

  Hamada, Tomoyuki ^a   Kubo, Toru ^a   Kitaoka, Hiroaki ^a   Hirota, Takayoshi ^a   Hoshikawa, Eri ^a   Hayato, Kayo ^a   Shimizu, Yuji ^a   Okawa, Makoto ^a   Yamasaki, Naohito ^a   Matsumura, Yoshihisa ^a   Yabe, Toshikazu ^a   Takata, Jun ^a   Doi, Yoshinori L ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DYSPNEA; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; SURVIVAL RATE; AGED; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPLICATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DYSPNEA; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; KAPLAN-MEIER ESTIMATE;

EID: 77954906656     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20533     Document Type: Article

References (15)

1. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002;287:1308-1320.
2. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858-864.
3. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl JMed. 1989;320:749-755.
4. Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinesis evolution of hypertrophic cardiomyopathy. Prevalence, incidence, risk factors, and prognostic implications in pediatrics and adult patients. J Am Coll Cardiol. 2005;46:1543-1550.
5. Thaman R, Gimeno JR, Mutphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91:920-925.
6. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-225.
7. Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005;46:1737-1743.
8. Matsumura Y, Takata J, Kitaoka H, et al. Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years. Circ J. 2006;70:376-383.
9. Kitaoka H, Kubo T, Okawa M, Hitomi N, Furuno T, Doi YL. Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in a rural community. Circ J. 2006;70:1543-1549. (Pubitemid 44819867)
10. Walter TA, Hister WL, Capehart JE, Roberts WC. Comparison of clinical and morphologic cardiac findings in patients having cardiac transplantation for ischemic cardiomyopathy, idiopathic dilated cardiomyopathy, and dilated hypertrophic cardiomyopathy. Am J Cardiol. 1998;81:884-894.
11. Lim D, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791. (Pubitemid 32163874)
12. Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, survival in rat heart failure. Circulation. 2001;103:148-154. (Pubitemid 32050450)
13. Rogers DPS, Marazia S, Chow AW, et al. Effect of biventricular pacing on symptoms and cardiac remodeling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2008;10:507-513.
14. Maron BJ, Shen W, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373.
15. Moon JC, Reed E, Sheppard MN, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-2264.